(51) International Patent Classification: G01N 33/68, 33/574, C12Q 1/44

(21) International Application Number: PCT/EP2004/002065

(22) International Filing Date: 27 February 2004 (27.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03005386.2 13 March 2003 (13.03.2003) EP

(71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report: 23 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTICS AND THERAPEUTICS FOR DISEASES ASSOCIATED WITH PHOSPHODIESTERASE 1B (PDE1B)

(57) Abstract: The invention provides a human PDE1B which is associated with the cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, metabolic diseases, gastrointestinal and liver diseases, cancer disorders, hematological disorders, respiratory diseases, neurological disorders and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1B as well as pharmaceutical compositions comprising such compounds.
A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N3/68 G01N3/574 C12Q1/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, BIOSIS, PAJ, WPI Data, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP 1 085 092 A (PFIZER LTD; PFIZER (US)) 21 March 2001 (2001-03-21) paragraph [0248] - paragraph [0330]; claims 9,11,12</td>
<td>1-25</td>
</tr>
<tr>
<td>P,X</td>
<td>WO 03/020702 A (CHILDREN'S HOSP MEDICAL CENTER; UNIV ROCKEFELLER (US)) 13 March 2003 (2003-03-13) page 16, line 24 - line 25; claims 5,19,27-33,53 page 44, last paragraph - page 45, paragraph 2</td>
<td>1-25</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. Patient family members are listed in annex.

* Special categories of cited documents:
   "A" document defining the general state of the art which is not considered to be of particular relevance
   "E" earlier document but published on or after the international filing date
   "L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
   "O" document referring to an oral disclosure, use, exhibition or other means
   "P" document published prior to the international filing date but later than the priority date claimed
   "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
   "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
   "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
   "S" document member of the same patent family

Date of the actual completion of the international search: 21 June 2004
Date of mailing of the international search report: 25.10.2004
Name and mailing address of the ISA:
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HM Rijswijk
Tel. (+31-70) 346-2040, Tx. 31 651 epo nl
Fax: (+31-70) 346-3016

Authorized officer
Gunster, M
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5 885 834 A (EPSTEIN PAUL M) 23 March 1999 (1999-03-23) cited in the application claim 1</td>
<td>19-21</td>
</tr>
<tr>
<td>A</td>
<td>YU JOSEPHINE ET AL: &quot;Identification and characterisation of a human calmodulin-stimulated phosphodiesterase PDE1B1&quot; CELLULAR SIGNALLING, vol. 9, no. 7, 1997, pages 519-529, XP002285173 ISSN: 0898-6568 cited in the application figure 5</td>
<td>1-25</td>
</tr>
<tr>
<td>A</td>
<td>RYBALKIN SERGEI D ET AL: &quot;Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype&quot; JOURNAL OF CLINICAL INVESTIGATION, vol. 100, no. 10, 15 November 1997 (1997-11-15), pages 2611-2621, XP002285174 ISSN: 0021-9738 page 2629, column 1, paragraph 4 - column 2, paragraph 2</td>
<td>1-25</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No.</td>
</tr>
<tr>
<td>----------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
</tbody>
</table>

Form PCT/ISA/10 (continuation of second sheet) (January 2004)
# International Search Report

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. **X** Claims Nos.: 26 because they relate to subject matter not required to be searched by this Authority, namely:
   - Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

2. **☐** Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. **☐** Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 5.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- see additional sheet

1. **☐** As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. **☐** As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. **☐** As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. **X** No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
   - 1 - 26 (partially)

### Remark on Protest

- **☐** The additional search fees were accompanied by the applicant's protest.
- **☐** No protest accompanied the payment of additional search fees.

---

Form PCT/ISA/219 (continuation of first sheet (2)) (January 2004)
Continuation of Box II.1
Claims Nos.: 26

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are cardiovascular diseases.

2. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are metabolic diseases.

3. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are gastrointestinal diseases.

4. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are liver diseases.

5. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are cancer disorders.

6. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are hematological diseases.

7. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are respiratory diseases.

8. claims: 1-26[partially]
Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are neurological disorders.

9. claims: 1-26[partially]

Diagnostics, therapeutics and methods of screening for therapeutics, relating to diseases associated with PDE1B, in which the diseases are urological diseases.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>JP 2001149084 A</td>
<td>05-06-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 03020702 A2</td>
<td>13-03-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1087101 A</td>
<td>09-07-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2395543 A1</td>
<td>05-07-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1434799 T</td>
<td>06-08-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1244620 A1</td>
<td>02-10-2002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2003519123 T</td>
<td>17-06-2003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0147880 A1</td>
<td>05-07-2001</td>
</tr>
<tr>
<td>US 5885834 A</td>
<td>23-03-1999</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>